Immutrin is a biotechnology company developing the next generation antibody therapy to deplete systemic amyloid deposits and reverse amyloidosis. The Company’s lead asset is being developed for the treatment of ATTR cardiomyopathy, a serious and progressive form of amyloidosis. Immutrin‘s antibody is a potential best-in-class therapy, with a unique mechanism of action designed to selectively and exclusively remove established amyloid fibrils.
Immutrin was co-founded by Cambridge Innovation Capital, academic founders Professor Sir Mark Pepys, FRS; Nobel Laureate Sir Gregory Winter, FRS; and Professor Daniel Christ and is built on decades of scientific and clinical leadership in amyloidosis combined with groundbreaking antibody expertise in drug development.
R1 Therapeutics is a clinical-stage biopharmaceutical company focusing on the development of first-in-class therapies for patients with kidney disease. Its lead program, AP306, targets hyperphosphatemia in patients with chronic kidney disease on dialysis, a condition associated with serious bone and cardiovascular complications and poorer outcomes when phosphate remains uncontrolled. AP306 is a first-in-class pan phosphate active transporter inhibitor with the potential to deliver rapid and effective phosphate lowering with a significantly reduced treatment burden. R1 is advancing AP306 in a global Phase 2b development program.
Quarry Thera is a biotech company advancing next-generation proximity-induced therapeutics using molecular glues. Molecular glues represent a powerful new drug modality, leveraging proprietary DNA-encoded libraries, structure-based design, and advanced medicinal chemistry to overcome challenges like limited efficacy, poor permeability, and the difficulty of targeting undruggable proteins.
iRiva Medical is developing next-generation neuromodulation technology aimed at treating chronic diseases. The company focuses on addressing unmet clinical needs for large patient populations through innovative implantable medical devices.
Arnatar is reimagining RNA medicines to precisely silence disease drivers or restore what’s missing. Through their dual-modality DARGER™ platform, they develop best-in-class siRNA and first-in-class upregulating ASOs for cardiometabolic, liver, CNS, and kidney diseases.
Apreo Health is redefining interventional pulmonology with a non-destructive, tissue-sparing solution for severe emphysema—one of the most under-treated and misunderstood diseases in medicine. Apreo is led by a team with deep expertise in both pulmonary medicine and medical device innovation. The company is advancing a therapy purpose-built to expand access, simplify delivery, and transform the treatment pathway for patients with severe emphysema.
Dr. Namandjé N. Bumpus joined F-Prime in 2025, where she serves as a strategic advisor on regulatory science, regulatory affairs, and policy, bringing deep expertise from her previous roles as FDA Principal Deputy Commissioner and Chief Scientist. Before the FDA, Dr. Bumpus was the E.K. Marshall and Thomas H. Maren Professor and director of the Department of Pharmacology and Molecular Sciences at the Johns Hopkins University School of Medicine, where her research advanced understanding of drug metabolism, mechanisms of drug-induced toxicity, pharmacogenetics, bioanalytical chemistry, infectious disease pharmacology, and single cell biology. She completed her postdoctoral fellowship at The Scripps Research Institute and holds a PhD in pharmacology from the University of Michigan and a bachelor’s degree in biology from Occidental College.
Dr. Bumpus is a past-president of the American Society for Pharmacology and Experimental Therapeutics, a fellow of the American Association for the Advancement of Science, and a member of the National Academy of Medicine.
Catherine Stehman-Breen is a Venture Partner at F-Prime based in the Cambridge office, focusing on new company creation. She has more than 30 years of medical and biopharmaceutical experience. Prior to joining F-Prime, Catherine was CEO of Chroma Medicine, a company developing a novel epigenetic editing therapeutics platform where she built the company from inception. Previously, she was Chief Research and Development Officer at Obsidian Therapeutics, a cell therapy company developing engineered tumor infiltrating lymphocyte therapies for patients with solid tumors. As Entrepreneur in Residence at Atlas Venture, she worked closely with start-ups across a range of technologies and previously served as Chief Medical Officer at Sarepta Therapeutics. In addition, Catherine held various leadership roles at Regeneron and Amgen.
Catherine earned her MD from the University of Chicago. She completed her residency and nephrology fellowship training at the University of Washington, where she also received an MS in epidemiology. Catherine served as a faculty member in the division of nephrology and remains an affiliate associate professor in the University of Washington School of Public Health, with more than 90 publications in medical journals.
Laurus Bio is an integrated research-driven biomanufacturing organization specializing in precision fermentation and recombinant technology. They develop sustainable, animal-free proteins and growth factors, replacing animal-derived products in various industries. Laurus Bio also offers CDMO services for microbial fermentation-based manufacturing and product development.